Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin - Wikidata - awgldk - TriplyDB

Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin

Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin

http://www.wikidata.org/entity/Q35328760

about

The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction Biomarkers in heart failure with preserved ejection fraction Emerging Novel Therapies for Heart Failure Myocardial hypertrophy and its role in heart failure with preserved ejection fraction Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction What global diastolic function is, what it is not, and how to measure it Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study Risk factors for heart failure are associated with alterations of the LV end-diastolic pressure-volume relationship in non-heart failure individuals: data from a large-scale, population-based cohort.Traditional Chinese Medication Qiliqiangxin Protects Against Cardiac Remodeling and Dysfunction in Spontaneously Hypertensive Rats.Exploring Guidelines for Classification of Major Heart Failure Subtypes by Using Machine Learning.Outcome in Heart Failure with Preserved Ejection Fraction: The Role of Myocardial Structure and Right Ventricular Performance Dasatinib Attenuates Pressure Overload Induced Cardiac Fibrosis in a Murine Transverse Aortic Constriction Model Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure With Preserved Ejection Fraction Diastolic Left Ventricular Function in Relation to Urinary and Serum Collagen Biomarkers in a General Population.Phosphorylating Titin's Cardiac N2B Element by ERK2 or CaMKIIδ Lowers the Single Molecule and Cardiac Muscle Force Mechanical Regulation of Cardiac Aging in Model Systems.Pharmacological Strategies to Retard Cardiovascular Aging Right Ventricular Myocardial Stiffness in Experimental Pulmonary Arterial Hypertension: Relative Contribution of Fibrosis and Myofibril Stiffness.Early-stage heart failure with preserved ejection fraction in the pig: a cardiovascular magnetic resonance study.Obesity alters molecular and functional cardiac responses to ischemia/reperfusion and glucagon-like peptide-1 receptor agonism.Therapeutic potential of targeting microRNAs to regulate cardiac fibrosis: miR-433 a new fibrotic player.Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites.INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design.Heart failure with preserved ejection fraction: uncertainties and dilemmas.Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use.Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome.The current status of heart failure diagnostic biomarkers.PM2.5 exposure in utero contributes to neonatal cardiac dysfunction in mice.Experimental cardiac radiation exposure induces ventricular diastolic dysfunction with preserved ejection fraction.After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction.Pathways for salvage and protection of the heart under stress: novel routes for cardiac rejuvenation.Heart failure with preserved ejection fraction and skeletal muscle physiology.ω3-Polyunsaturated fatty acids for heart failure: Effects of dose on efficacy and novel signaling through free fatty acid receptor 4.Cardiovascular consequences of metabolic syndrome.Redefining the role of biomarkers in heart failure trials: expert consensus document.Therapeutic Targeting of PDEs and PI3K in Heart Failure with Preserved Ejection Fraction (HFpEF).Left Atrial Remodeling and Atrioventricular Coupling in a Canine Model of Early Heart Failure With Preserved Ejection Fraction.Tampering with springs: phosphorylation of titin affecting the mechanical function of cardiomyocytes.Alternative Splicing of Titin Restores Diastolic Function in an HFpEF-Like Genetic Murine Model (TtnΔIAjxn)

P2860

Q26765101-8A734DBE-FB5B-4872-8E1C-6B9CEE467488 Q26768192-703800E2-A495-43FD-8EBF-24A31A0F72F5 Q26778111-63C79DAD-A260-4FBD-8F29-E4A2E234A8B7 Q26800076-654F5236-025A-4132-8103-4B4453A53713 Q28073079-FB3283FB-159F-4BCE-A76A-2EDC6C030FFC Q28087043-1F476D8C-973D-47A2-A477-2375EC0230BA Q31036336-CCD44404-2814-4882-91F6-724D915D759C Q31071475-0A3430B1-1EEC-4BC0-9CB2-0868E2A80E3D Q33717198-103B6F11-E207-4579-AF4C-FB1141DF8AE7 Q35636729-F0F38741-2DD1-4CB8-86A3-F146F5F4E93D Q35725839-9821A75A-9B4A-443E-8876-033BB847401B Q35803480-0381FE38-A581-4450-BF92-14B82A7BB842 Q36181771-F2B9E125-0BEE-4AA1-B627-3F0EF92F93C9 Q36222011-55A73304-BEF5-4D4D-B41A-4499E6C07D72 Q36429564-691AF9A2-400F-4E08-BD2A-85D31986B845 Q36905133-5EC5E9C9-FA49-44B7-BAC4-F2E3C7911DE3 Q36972415-548D7AEC-20FF-486F-94CB-F8F39B7F2E84 Q37116376-AAB3D3BC-8FBE-4F41-9C01-6D0C8E6793A8 Q37299336-77AC55E1-9FB0-462F-A7DB-AFFDB6E55159 Q37468729-67D58150-C86C-43ED-9838-249F897E8F23 Q37583782-FB0C6CBC-163B-45C1-805F-D128AAF0AD9D Q37623540-DE5FA561-067B-4D06-AB58-7086E4E208AF Q38377133-0D09EBBD-2332-40A3-B4F7-846DCF2A425E Q38529003-D5EC8E19-C67C-4122-8F8A-2F6FDFAFA371 Q38593070-764C77F2-0BFE-4ED6-A090-76735F40D9C5 Q38614176-A514B491-36AA-4676-AA42-CD196D741E71 Q38646405-978A5D84-87B5-4B0B-BC79-0FCF0369B48E Q38703882-2BD6F736-FD8F-4854-9DA2-45CFECB64A6B Q38709683-DF2A7F2A-9E00-41BC-9958-00FCDE9C7893 Q38760688-6399620E-A3D1-481D-AB02-917848D5B539 Q38807777-576A91A1-B4B2-410B-8392-7CBD42402334 Q38884029-4B600806-0D05-4844-9AA5-594ADF90BED7 Q38931738-0E0BBE5C-3D66-496C-AAEA-34F6173D9BDE Q39041784-CC6CA5E8-F6E1-4907-9CD1-3D140177345D Q39106973-27CC1F30-AF74-4CBF-930C-7C46B82BAD1A Q39195160-80DE4CFC-D11F-4010-A4D3-D37C35F64695 Q39268911-5F4EDE62-E655-489C-A801-59D138B7BFA9 Q39272526-DDA5F5A9-9824-461C-AECC-C9EC2DDAC85C Q39310690-85F3591A-40A8-4583-811C-CB2E9BA34FA1 Q39547806-77B84CF6-A043-4E77-BCD9-E0D84FEE37C0

P2860

Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin

http://www.wikidata.org/entity/Q35328760

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Myocardial stiffness in patien ...... ibutions of collagen and titin

@ast

Myocardial stiffness in patien ...... ibutions of collagen and titin

@en

type

label

Myocardial stiffness in patien ...... ibutions of collagen and titin

@ast

Myocardial stiffness in patien ...... ibutions of collagen and titin

@en

prefLabel

Myocardial stiffness in patien ...... ibutions of collagen and titin

@ast

Myocardial stiffness in patien ...... ibutions of collagen and titin

@en

P1433

Q35328760-7CEC9BEB-9FE4-452C-B403-F610C9E63C14

P1476

Q35328760-4E91C419-8E70-4E5A-82CF-10B349958983

P2093

Q35328760-0D8E566B-6945-4E6B-BB99-99D5F3B5F192

Q35328760-1450C120-3FAD-4B4D-A319-602A759F9C0B

Q35328760-2E9E02B9-495D-44B3-BAFF-F940E73FA3C0

Q35328760-51637FC4-7872-4DBD-A96D-2C4AC16B480D

Q35328760-56AD6931-243F-4872-96EC-107067F465CE

Q35328760-630C6E72-0E82-4451-8DF6-C040188DF36C

Q35328760-65E5DC0E-61BF-44D1-A745-3C38AB128580

Q35328760-80F414E5-FAD8-4E9D-BA13-4AB25B28398E

Q35328760-C843D287-F961-493A-B0FC-531C24E02078

Q35328760-E737D0AC-92D4-43C0-A07A-8F4D106FE1D7

P2860

Q35328760-03C8823B-36DF-4575-BC22-192C4ABC601A

Q35328760-06965BC8-2BA1-4DB4-AD03-8ECC524D9706

Q35328760-0734C61E-AC06-47D9-B415-FC57D2257764

Q35328760-0786BBCD-26B6-4BED-9BB3-9737BAC1A88D

Q35328760-07ACBB13-71FA-40C7-903B-9913072C2A8E

Q35328760-0B0D1286-F46D-4E5E-99DB-F311AB9FBFB6

Q35328760-0B35F07D-92E3-4BE1-AAE2-688A14290A53

Q35328760-15FF0F05-9071-4E0A-A97B-742419283124

Q35328760-1E82E406-7D05-4707-9C8B-6EE5AA4ECDDC

Q35328760-20615E1F-F2F9-4088-828B-A8F723064293

P304

Q35328760-E32C06EF-ABEA-49B1-9717-8A8DBEF67C3A

P31

Q35328760-53B08CC7-B69D-42C2-8AA5-505D9672EE43

P356

Q35328760-6E1AE5B6-FF3E-4F2A-8775-4C15C879B2DE

P407

Q35328760-28C090EA-8712-4AC9-90DA-6A457BBE9B55

P433

Q35328760-32149AF5-2CAF-40F0-A853-2C47485E30EC

P478

Q35328760-E4FBB468-83F1-46FF-8A51-A2BC09932C34

P50

Q35328760-48BF09AC-6C44-4FE5-9649-D6E02291ACE7

Q35328760-B8FE0F38-C78B-49ED-82A4-2C776BF06D9D

P577

Q35328760-31961736-F7E7-4BC0-B3AD-63AF99988A49

P698

Q35328760-01CDBB4F-F2F9-4594-955B-B95C9B180697

P921

Q35328760-D74BC219-B397-4529-AA3F-3549294A2332

P932

Q35328760-341139E3-BFF5-4A65-87E4-DA50630D9F86

P356

CIRCULATIONAHA.114.013215

P1433

P1476

Myocardial stiffness in patien ...... ibutions of collagen and titin

@en

P2093

Amy D Bradshaw

http://www.w3.org/2001/XMLSchema#string

Bradley M Palmer

http://www.w3.org/2001/XMLSchema#string

Catalin F Baicu

http://www.w3.org/2001/XMLSchema#string

David A Bull

http://www.w3.org/2001/XMLSchema#string

Henk L Granzier

http://www.w3.org/2001/XMLSchema#string

John S Ikonomidis

http://www.w3.org/2001/XMLSchema#string

Margaret M Redfield

http://www.w3.org/2001/XMLSchema#string

Martin M LeWinter

http://www.w3.org/2001/XMLSchema#string

Paul J Nietert

http://www.w3.org/2001/XMLSchema#string

Peter Van Buren

http://www.w3.org/2001/XMLSchema#string

P2860

Crucial role for Ca2(+)/calmodulin-dependent protein kinase-II in regulating diastolic stress of normal and failing hearts via titin phosphorylation

A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation

Heart failure with preserved ejection fraction

Trends in prevalence and outcome of heart failure with preserved ejection fraction

Outcome of heart failure with preserved ejection fraction in a population-based study

PKC-alpha regulates cardiac contractility and propensity toward heart failure

Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Fail

Extensible behavior of titin in the miniswine left ventricle.

Excision of titin's cardiac PEVK spring element abolishes PKCalpha-induced increases in myocardial stiffness

HFSA 2010 Comprehensive Heart Failure Practice Guideline.

P304

1247-1259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.114.013215

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

131

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25637629

http://www.w3.org/2001/XMLSchema#string

P921

P932

4390480

http://www.w3.org/2001/XMLSchema#string